Methylation Analysis of \textit{P16, RASSF1A, RPRM,} and \textit{RUNX3} in Circulating Cell-Free DNA for Detection of Gastric Cancer: A Validation Study

Kioomars Saliminejad 1,2, Shahrzad Soleymani Fard 1, Hamid Reza Khorram Khorshid 3, Marjan Yaghmaie 1, Habibollah Mahmoodzadeh 4, Seyed Asadollah Mousavi 1, and Seyed Hamidollah Ghaffari 1*

1. Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Reproductive Biotechnology Research Center, Avicenna Research Institute, (ACECR), Tehran, Iran
3. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
4. Department of Surgery, Cancer Institute, Imam Khomeini Hospital, Tehran, University of Medical Sciences, Tehran, Iran

Abstract

\textbf{Background:} Most of Gastric Cancer (GC) patients are diagnosed at an advanced stage with poor prognosis. Hypermethylations of several tumor suppressor genes in cell-free DNA of GC patients have been previously reported. In this study, an attempt was made to investigate the methylation status of \textit{P16, RASSF1A, RPRM,} and \textit{RUNX3} and their potentials for early diagnosis of GC.

\textbf{Methods:} Methylation status of the four tumor suppressor genes in 96 plasma samples from histopathologically confirmed gastric adenocarcinoma patients (Stage I-IV) and 88 healthy controls was determined using methylation-specific PCR method. Receiver operating characteristic curve analysis was performed and Area Under the Curve (AUC) was calculated. Two tailed \(p<0.05\) were considered statistically significant.

\textbf{Results:} Methylated \textit{P16, RASSF1A, RPRM,} and \textit{RUNX3} were significantly higher in the GC patients (41.7, 33.3, 66.7, and 58.3\%) compared to the controls (15.9, 0.0, 6.8, and 4.5\%), respectively (\(p<0.001\)). Stratification of patients showed that \textit{RPRM} (AUC: 0.70, Sensitivity: 0.47, Specificity: 0.93, and \(p<0.001\)) and \textit{RUNX3} (AUC: 0.77, Sensitivity: 0.59, Specificity: 0.95, and \(p<0.001\)) had the highest performances in detection of early-stage (I+II) GC. The combined methylation of \textit{RPRM} and \textit{RUNX3} in detection of early-stage GC had a higher AUC of 0.88 (SE=0.042; 95\% CI:0.793–0.957; \(p<0.001\)), higher sensitivity of 0.82 and reduced specificity of 0.89.

\textbf{Conclusion:} Methylation analysis of \textit{RPRM} and \textit{RUNX3} in circulating cell-free-DNA of plasma could be suggested as a potential biomarker for detection of GC in early-stages.


\textbf{Keywords:} Biomarkers, Cell-free DNA, Gastric cancer, DNA methylation

Introduction

Gastric Cancer (GC) is the third leading cause of cancer-related mortality globally 1. Diagnosis of early-stage GC is still difficult, and in fact, most of them are diagnosed at an advanced stage with a poor prognosis 2. Currently, invasive endoscopy followed by pathological diagnosis is the gold standard for GC diagnosis 3. Single-lesion tumor-biopsy could not reflect the tumor heterogeneity, which could result in the treatment failure and drug resistance 4. In addition, the low sensitivity and specificity of available blood biomarkers are not satisfactory for early diagnosis of GC 2.

Epigenetic changes, including aberrant DNA methylation, are common in all types of cancers including gastrointestinal, and contribute to both initiation of cancer and progression 5. Deregulation of epigenetic modifications may actually even precede classical genetic changes in various oncogenes and tumor suppressor genes 6. Aberrant DNA methylation is not just a feature of advanced-stage, but also an early and driver event in GC 7, and could be non-invasively identified in cell-free DNA (cfDNA) of cancer patients 5.
Aberrant methylation of several tumor suppressor genes including RUNX3, P16, RASSF1A, ZIC1, RPRM, CDH1, and SOX17 as potential biomarkers for early detection of GC has been identified. However, to become a clinically approved test, a potential biomarker should be confirmed and validated in inter- and intra-laboratory studies using hundreds of specimens. The first step in finding a biomarker usually begins with studies of tumor tissues and non-tumor tissues. Previous studies showed that the methylation of RUNX3, RASSF1A, RPRM, and RUNX3 was significantly higher in primary GC tissues compared to the corresponding normal gastric tissues.

P16, a cell cycle regulator, controls the G1 phase of cell cycle to S phase, and inhibits CDK4 and CDK6. RASSF1A, a putative tumor suppressor gene, plays an important role in regulation of cell cycle, apoptosis, and microtubule stability through the regulation of Ras signaling. RPRM in response to p53 expression arrests cell cycle at G2/M, and its expression is inversely associated with the cell proliferation and growth in GC. RUNX3 is a tumor suppressor gene considered as a downstream effector of the TGF-β signaling pathway.

Previous studies using the serum or plasma samples have shown that methylation of the RASSF1A, RUNX3, RPRM, and P16, as potential diagnostic biomarkers, could be suggested for early detection of GC. In this study, an attempt was made to investigate and validate the potential of these tumor suppressor genes as diagnostic biomarkers in the plasma of GC patients and normal controls.

Materials and Methods

Subjects

Altogether, 184 plasma samples from 88 normal controls, and 96 histopathologically confirmed gastric adenocarcinoma patients with various Tumor-Node-Metastasis (TNM) stages (I–IV) were collected. The plasma samples were collected prior to surgery, chemotherapy, and/or radiotherapy. Participants were enrolled from the Department of Surgery, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. The patients were followed-up until death or to the end of the study. The study was approved by the ethics committee of the Tehran University of Medical Sciences (Ethics code: IR.TUMS.VCR.REC.1395.1078), and written informed consent was obtained from all patients.

DNA extraction from plasma samples

From each participant, 5 ml of peripheral blood was collected in 200 μL of 0.5 M EDTA. To separate the plasma, the blood samples were immediately centrifuged at 3000g for 10 min at 4°C. The plasma was collected and transferred to new tubes and stored at!80°C. Circulating cfDNAs was extracted from 2 ml of plasma samples by the QIAamp Circulating Nucleic

Acid Kit (Qiagen, Germany) according to the manufacturer’s protocol. The concentrations of cfDNAs were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).

For all samples, before proceeding to sodium bisulfite conversion step, the accuracy of cfDNAs extractions were assessed by amplifying TBP (TATA-binding protein) gene using the forward 5'-CACAGACTTCCACA ACTGCGAC-3' and reverse primer 5'-ACAATCCCG ACTCTTCGTAG-3'. The 115 bp PCR products of the TBP housekeeping gene were amplified in all cfDNAs extracted in the plasma of GC patients as well as control samples.

Sodium bisulfite conversion

For each sample, 40 μL of cfDNA was modified with sodium bisulfite using the EpiTect Bisulfite Kit (Qiagen, Germany) according to the manufacturer’s protocol of sodium bisulfite conversion of unmethylated cytosines in DNA from low-concentration solutions. Purified modified DNA was eluted in 30 μL of DDW and stored at -80°C until use.

Methylation specific PCR

The methylation status of the P16, RASSF1A, RPRM, and RUNX3 promoters in cfDNA samples was detected by conventional methylation specific PCR (MSP) by specific primer pairs for both the methylated and unmethylated status (Table 1). Each MSP reaction was performed in a total volume of 12 μL. Briefly, 2 μL of sodium bisulfite converted DNA was added into a reaction mixture containing 6 μL of 2x master mix (Ampliqon, Denmark), and 1 μL of the corresponding forward and reverse primers (10 μM); finally ddw was added to a final volume of 12 μL. Amplification conditions for both methylated and unmethylated reactions were as follows: an initial denaturation of 95°C for 5 min, followed by 45 cycles of 95°C for 35 s, annealing temperature of 57-67°C for 35 s, and extension of 72°C for 35 s, and finally an extension of 72°C for 10 min. The MSP products were electrophoresed on 2% agarose gels, stained with ethidium bromide, and visualized under UV light (Figure 1).

Statistical analysis

Statistical analysis of the data was performed using the SPSS version 16.0 (SPSS Inc, Chicago, IL). The methylation status and the other qualitative variables were expressed as frequencies and percentages. Continuous variables were compared by Student’s t test, while categorical data were checked by Chi-square or Fisher’s exact tests where appropriate. Receiver Operating Characteristic (ROC) curve and the Area Under the Curve (AUC) were used to assess the performance of the biomarkers and the higher AUCs were considered as better diagnostic performance. A logistic regression model was performed to evaluate the diagnostic performance of the combination of the biomarkers. Survival rates were calculated with the Kaplan-Meier method and the statistical difference between survival
curves was determined with log-rank test. Two tailed p-value <0.05 was considered statistically significant.

Results

Descriptive analysis of the subjects

The mean age of GC patients and healthy controls were 59.5±12.3 and 56.1±11.3, respectively. The female to male gender ratio in the control and GC groups were 26/62 and 34/62, respectively. No significant difference was found in the distribution of age (p=0.052) and gender (p=0.434) among the GC patients and the normal healthy controls. In the GC group, the ratio of males (n=62) to females (n=34) was nearly twice. Classification of the GC patients according to the TNM classification showed that 35.4% (34/96) and 64.6% (62/96) of the tumors were early (I+II) and advanced-stages (III+IV), respectively.

Methylation rates and performances of the candidate genes

The P16, RASSF1A, RPRM, and RUNX3 promoters were found to be methylated in 40 (41.7%), 32 (33.3%), 64 (66.7%), and 56 (58.3%) of the 96 GC samples, respectively. Alternatively, the P16, RASSF1A, RPRM, and RUNX3 promoters were found to be methylated in 14 (15.9%), 0 (0.0%), 6 (6.8%) and 4 (4.5%) of the 88 control samples, respectively (Table 2). Unmethylated-specific primers for the P16, RASSF1A, RPRM, and RUNX3 were amplified in all subjects. There was no significant association between methylation of four candidate genes and gender. In addition, stratification of subjects by ages (<60 and >60) showed that there were no significant association between methylation of RASSF1A, RPRM, and RUNX3 and ages. However, methylated P16 was significantly higher in the subjects over 60 years old compared to the subjects under 60 years old (p=0.006).

Methylation rates increased in the progression of gastric carcinogenesis from the controls to the early and advanced-stages GC samples for the P16, RASSF1A, and RPRM genes (Figure 2). Concurrent methylation in two or more genes was found in 77.1% (74/96) of plasma GC samples and 0.0% of normal plasma. On the other hand, 4.2% (4/96) of GC samples and 75% (66/88) of controls were methylation free for the P16,
Methylation Analysis of cfDNA for Detection of Gastric Cancer

Avicenna Journal of Medical Biotechnology, Vol. 12, No. 2, April-June 2020

RASSF1A, RPRM, and RUNX3. Analysis of the biomarkers performances in patients (TM stages I–IV) showed that the AUC of RPRM, RUNX3, RASSF1A, and P16 were 0.80 (SE=0.034; 95% CI: 0.733-0.866), 0.77 (SE=0.036; 95% CI: 0.699-0.839), 0.67 (SE=0.040; 95% CI: 0.589-0.745), and 0.63 (SE=0.041; 95% CI: 0.548-0.709), respectively (Figure 3).

To explore the potentials of methylation analysis of these genes in early detection of GC, the performances of RPRM, RUNX3, RASSF1A, and P16 in early-stage GC patients (I+II) were analyzed in comparison to the controls. The results showed that RUNX3 (p<0.001) with an AUC of 0.77 (SE=0.055; 95% CI: 0.664-0.879), sensitivity of 0.59, and specificity of 0.95, and RPRM (p<0.001) with an AUC of 0.70 (SE=0.059; 95% CI: 0.586-0.816), sensitivity of 0.47, and specificity of 0.93 could discriminate the early-stage GC patients from the normal controls with the highest performances (Table 2). Although methylation frequency of P16 (p=0.026) and RASSF1A (p<0.001) was significantly different between the early-stage GC patients and the healthy people, however, they were excluded from further analysis due to their low sensitivities of 0.35 and 0.24, respectively (Table 2).

Table 2. Methylation frequencies of the P16, RASSF1A, RPRM, and RUNX3 in the subjects and their performances in detection of gastric cancer with various stages

<table>
<thead>
<tr>
<th>Gene</th>
<th>TNM stage</th>
<th>Gastric cancer (n=96)</th>
<th>Controls (n=88)</th>
<th>p-value</th>
<th>AUC</th>
<th>S</th>
<th>Sp</th>
<th>PPV</th>
<th>NPV</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Met (%)</td>
<td>Met (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P16</td>
<td>I+II</td>
<td>12/34 (35.3%)</td>
<td>14/88 (15.9%)</td>
<td>0.026</td>
<td>0.60</td>
<td>0.35</td>
<td>0.84</td>
<td>0.46</td>
<td>0.77</td>
<td>0.71</td>
</tr>
<tr>
<td></td>
<td>III+IV</td>
<td>28/62 (45.2%)</td>
<td>14/88 (15.9%)</td>
<td>p&lt;0.001</td>
<td>0.65</td>
<td>0.45</td>
<td>0.84</td>
<td>0.67</td>
<td>0.69</td>
<td>0.68</td>
</tr>
<tr>
<td></td>
<td>I-IV</td>
<td>40/96 (41.7%)</td>
<td>14/88 (15.9%)</td>
<td>p&lt;0.001</td>
<td>0.63</td>
<td>0.42</td>
<td>0.84</td>
<td>0.74</td>
<td>0.57</td>
<td>0.62</td>
</tr>
<tr>
<td>RASSF1A</td>
<td>I+II</td>
<td>8/34 (23.5%)</td>
<td>14/88 (15.9%)</td>
<td>p&lt;0.001</td>
<td>0.62</td>
<td>0.24</td>
<td>1.0</td>
<td>1.0</td>
<td>0.77</td>
<td>0.79</td>
</tr>
<tr>
<td></td>
<td>III+IV</td>
<td>24/62 (38.7%)</td>
<td>0/88</td>
<td>p&lt;0.001</td>
<td>0.69</td>
<td>0.39</td>
<td>1.0</td>
<td>1.0</td>
<td>0.70</td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>I-IV</td>
<td>32/96 (33.3%)</td>
<td>14/88 (15.9%)</td>
<td>p&lt;0.001</td>
<td>0.67</td>
<td>0.33</td>
<td>1.0</td>
<td>1.0</td>
<td>0.58</td>
<td>0.65</td>
</tr>
<tr>
<td>RPRM</td>
<td>I+II</td>
<td>16/34 (47.1%)</td>
<td>6/88</td>
<td>p&lt;0.001</td>
<td>0.70</td>
<td>0.47</td>
<td>0.93</td>
<td>0.73</td>
<td>0.82</td>
<td>0.80</td>
</tr>
<tr>
<td></td>
<td>III+IV</td>
<td>48/62 (77.4%)</td>
<td>6/88 (6.8%)</td>
<td>p&lt;0.001</td>
<td>0.85</td>
<td>0.77</td>
<td>0.93</td>
<td>0.89</td>
<td>0.85</td>
<td>0.87</td>
</tr>
<tr>
<td></td>
<td>I-IV</td>
<td>64/96 (66.7%)</td>
<td>6/88</td>
<td>p&lt;0.001</td>
<td>0.80</td>
<td>0.67</td>
<td>0.93</td>
<td>0.91</td>
<td>0.72</td>
<td>0.79</td>
</tr>
<tr>
<td>RUNX3</td>
<td>I+II</td>
<td>20/34 (58.8%)</td>
<td>4/88 (4.5%)</td>
<td>p&lt;0.001</td>
<td>0.77</td>
<td>0.59</td>
<td>0.95</td>
<td>0.83</td>
<td>0.86</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>III+IV</td>
<td>36/62 (58.1%)</td>
<td>4/88 (4.5%)</td>
<td>p&lt;0.001</td>
<td>0.76</td>
<td>0.58</td>
<td>0.95</td>
<td>0.90</td>
<td>0.76</td>
<td>0.80</td>
</tr>
<tr>
<td></td>
<td>I-IV</td>
<td>56/96 (58.3%)</td>
<td>4/88</td>
<td>p&lt;0.001</td>
<td>0.77</td>
<td>0.58</td>
<td>0.95</td>
<td>0.93</td>
<td>0.68</td>
<td>0.76</td>
</tr>
</tbody>
</table>

TNM: Tumor-Node-Metastasis; AUC: Area under the curve; S: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value.

* Fisher’s exact tests.

Figure 3. Performance of the candidate biomarkers. A) Receiver operating characteristic (ROC) for methylation status of the P16, RASSF1A, RPRM, and RUNX3 in detection of gastric cancer (I–IV). B) ROC analysis of the combined RPRM and RUNX3 methylation status in detection of early-stage gastric cancer (I+II). AUC: Area under curve; SE: Standard error; 95% CI: 95% Confidence interval.
Since the sensitivity of a single gene methylation was still unsatisfying, combined detection of several genes might be a solution. A logistic regression model was performed to evaluate the diagnostic performance of the combination of the RPRM, and RUNX3 biomarkers in discriminating between early-stage GC (I+II) and normal controls (Figure 3). Our results showed that combination of RPRM and RUNX3 increased the AUC to 0.88 (SE=0.042; 95% CI: 0.793-0.957), and sensitivity to 0.82; however, the specificity decreased to 0.89 (p<0.001).

Correlations between methylation status and survival

After a median follow up period of 20 months, 16.7% (16/96) of patients died because of the disease progression. The P16, RASSF1A, RPRM, and RUNX3 methylation were detected in 50% (8/16), 37.5% (6/16), 87.5% (14/16), and 87.5% (14/16) of these patients, respectively. Among the entire cohort, the mean survival time was 18.1 months (SE=0.422; 95% CI: 17.2-18.9).

Patients’ survival as depicted in figure 4 was significantly associated with methylation status of RUNX3 (p=0.027). On the other hand, patients’ survival was not significantly associated with methylation status of P16 (p=0.719), RASSF1A (p=0.750), RPRM (p=0.073). Mean survival time (months) of patients with a methylated P16, RASSF1A, RPRM, and RUNX3 were 18.0±0.61 (95% CI: 16.8-19.2), 18.9±0.34 (95% CI: 18.2-19.6), 17.7±0.53 (95% CI: 16.6-18.7), and 17.4±0.59 (95% CI: 16.2-18.5), respectively. In addition, mean survival time (months) of patients with an unmethylated P16, RASSF1A, RPRM, and RUNX3 were 18.2±0.58 (95% CI: 17.1-19.3), 17.9±0.58 (95% CI: 16.8-19.1), 19.1±0.59 (95% CI: 17.9-20.3), and 19.4±0.38 (95% CI: 18.7-20.1), respectively.

**Discussion**

In the present study, an attempt was made to investigate the methylation status of four potential candidate genes in circulating cfDNA of plasma in GC patients and healthy controls, and their possible correlations with tumor stage, gender, age, and survival were examined. Our results showed that P16, RASSF1A, RPRM, and RUNX3 promoters were methylated in 41.7, 33.3, 66.7, and 58.3% of the GC patients (I-IV), and in 15.9, 0.0, 6.8 and 4.5% of the healthy controls, respectively (p<0.001). No significant correlation was found between the methylation status of four candidate genes and gender. Analysis of methylation status with the ages (≤60 versus >60) showed that methylated P16 was
Methylation Analysis of cfDNA for Detection of Gastric Cancer

Table 3. Methylation rates of the P16, RASSF1A, RPRM, and RUNX3 in diagnosis of gastric cancer using serum or plasma samples

<table>
<thead>
<tr>
<th>Gene</th>
<th>Source</th>
<th>Gastric cancer</th>
<th>Control</th>
<th>Country</th>
<th>Method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P16</strong></td>
<td>Serum</td>
<td>51.9%</td>
<td>0.0%</td>
<td>Hong Kong</td>
<td>MSP</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>26.9%</td>
<td>0.0%</td>
<td>Iran</td>
<td>MSP</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>79.7%</td>
<td>2.5%</td>
<td>China</td>
<td>MSP</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>41.7%</td>
<td>15.9%</td>
<td>Iran</td>
<td>MSP</td>
<td>This Study</td>
</tr>
<tr>
<td><strong>RASSF1A</strong></td>
<td>Serum</td>
<td>34.0%</td>
<td>0.0%</td>
<td>China</td>
<td>MSP</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>68.5%</td>
<td>0.0%</td>
<td>Greece</td>
<td>MSP</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>83.2%</td>
<td>5.5%</td>
<td>Thailand</td>
<td>MSP</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>33.3%</td>
<td>0.0%</td>
<td>Iran</td>
<td>MSP</td>
<td>This Study</td>
</tr>
<tr>
<td><strong>RPRM</strong></td>
<td>Plasma</td>
<td>95.3%</td>
<td>9.7%</td>
<td>Chile</td>
<td>MSP</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>62.0%</td>
<td>0.0%</td>
<td>China</td>
<td>MSP</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>94.3%</td>
<td>7.1%</td>
<td>China</td>
<td>MS-MCA</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>86.3%</td>
<td>7.9%</td>
<td>China</td>
<td>BS</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>66.7%</td>
<td>6.8%</td>
<td>Iran</td>
<td>MSP</td>
<td>This Study</td>
</tr>
<tr>
<td><strong>RUNX3</strong></td>
<td>Serum</td>
<td>29.0%</td>
<td>0.0%</td>
<td>Japan</td>
<td>qMSP</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Serum</td>
<td>70.8%</td>
<td>0.0%</td>
<td>China</td>
<td>qMSP</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>42.7%</td>
<td>0.0%</td>
<td>China</td>
<td>MSP</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>58.3%</td>
<td>4.5%</td>
<td>Iran</td>
<td>MSP</td>
<td>This Study</td>
</tr>
</tbody>
</table>

MS-MCA: Methylation sensitive melt curve analysis; MSP: Methylation specific PCR; qMSP: quantitative MSP; BS: Bisufite sequencing.

significantly higher in the subjects over 60 years old compared to the subjects under 60 years old (p=0.006). Analysis of overall survival with methylation status of the four candidate biomarkers showed that patients’ survival was significantly associated with methylation status of RUNX3 (p=0.027).

The methylation rates in our study were similar to the results of previous studies. The results of previous studies on serum/plasma, which have evaluated the diagnostic potentials of the candidate genes methylation, are summarized in table 3 according to the previous studies by serum and plasma samples, the mean methylation rates of P16, RASSF1A, RPRM, and RUNX3 were 52.8, 61.9, 84.5, and 47.5% in the GC patients and 0.8, 1.8, 6.2, and 0.0% in the control groups, respectively. Evaluation of their findings revealed that variations in the results were lower in the controls compared to the GC groups. The methylation rates of previous studies in the GC groups for P16, RASSF1A, RPRM and RUNX3 ranged from 26.9-79.7, 34.0-83.2, 62.0-95.3, and 29.0-70.8%, respectively. These discrepancies could be explained by several factors. First, various methods with different sensitivity including MSP, qMSP, and bisufite sequencing have been used for analysis of methylation status of the relevant gene in each study. Second, methylation specific primers have been designed in different CpG sites for each gene. Analysis of eight CpG sites in RUNX3 promoter by quantitative pyrosequencing has shown that methylation frequencies of only six specific sites were different between GC and normal gastric tissues.

Our results showed that the methylation rates increased in the progression of gastric carcinogenesis from the control to the early and advanced-stage GC for the P16, RASSF1A, and RPRM genes. Increasing the methylation rate could be explained by the fact that more cfDNA gets into systemic circulation with enhancement of the disease. In addition, concurrent methylations in two or more genes were found in 77.1% of plasma GC samples and 0.0% of normal plasma. On the other hand, 4.2% of GC patients and 75.0% of controls were methylation free for all four genes.

Also, the performances of candidate biomarkers in early-stage GC patients (I+II) were analyzed. The results showed that RUNX3 with an AUC of 0.77, sensitivity of 0.59, and specificity of 0.95, and RPRM with an AUC of 0.70, sensitivity of 0.47, and specificity of 0.93 could discriminate the early-stage GC from normal controls with the highest performances (p<0.001). Although P16 (p=0.026) and RASSF1A (p<0.001) could also discriminate the early-stage patients from the controls, their sensitivities were very low as 0.35 and 0.24, respectively. For that reason, they were excluded from further analysis.

The sensitivity and specificity of RUNX3 hypermethylation by qMSP, in serum samples of GC pa-
tients and normal controls in a study by Lu et al were 70.8 and 99.8%, respectively \(^\text{30}\). In another study by Lin et al, the sensitivity and specificity of \(\text{RUNX3}\) hypermethylation were 42.7 and 79.2%, respectively \(^\text{20}\). Our results were similar to the study by Lin et al which used MSP as the method for methylation detection \(^\text{20}\). The higher performance of \(\text{RUNX3}\) methylation in the study by Lu et al might be explained by the fact that \(\text{qMSP}\) is more sensitive than MSP \(^\text{30}\).

The use of only a single gene to discriminate cancer patients from the healthy people has several drawbacks. First, the maximum sensitivity of a test by only a single gene could be as high as the rate of methylation for that gene. Second, non-cancerous tissues could be occasionally methylated at the same gene locus as cancerous tissue \(^\text{33}\). Furthermore, methylation of a single gene locus can occur in different cancers. For example, in addition to GC, aberrant methylation of \(\text{P16}\) and \(\text{RASSF1A}\) in serum of breast cancer patients \(^\text{34}\), hypermethylation of \(\text{RASSF1A}\) in hepatocellular carcinoma tissues \(^\text{35}\), and hypermethylation of \(\text{RUNX3}\) in serum of colorectal cancer patients have also been reported \(^\text{38}\). For that reason, a panel of hypermethylated genes, instead of a single gene, could be more effective to guarantee that the biomarker is specific to a cancer.

Also, the combination of \(\text{RPRM}\) and \(\text{RUNX3}\) in distinguishing the early-stage GC (I+II) from the controls was analyzed. The results showed a higher AUC of 0.88, with a higher sensitivity of 0.82 and reduced specificity of 0.89 (\(p<0.001\)). Although the specificity of combined detection of \(\text{RPRM}\) and \(\text{RUNX3}\) methylation was lower than that of single gene assays, the sensitivity was increased.

**Conclusion**

In conclusion, combined detection of plasma \(\text{RPRM}\), and \(\text{RUNX3}\) methylation could be suggested as a potential strategy for early diagnosis of GC; however, further studies for validation of the panel are required.

**Acknowledgement**

The study was supported by a grant from the Hematology, Oncology, and Stem Cell Transplantation Research Centre, Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran.

**Conflict of Interest**

The authors have no conflicts of interest to declare.

**References**

Methylation Analysis of cfDNA for Detection of Gastric Cancer


